Orion Armon

Cooley successfully defeated an emergency motion for injunction for Samsung in Alexion Pharmaceuticals, Inc. et al. v. Samsung Bioepis Co. Ltd. before District Judge Gregory Williams in ongoing Biologics Price Competition and Innovation Act (BPCIA) litigation for its proposed biosimilar Soliris, which is used to treat blood disorders.

Cooley represented Sight Sciences (listed as SGHT on Nasdaq), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, which received a jury trial win on April 26, 2024, against its competitors – Alcon, Alcon Vision and Alcon Research (collectively known as Alcon) and Ivantis – in the US District Court for the District of Delaware.

Cooley represented OpenText in a patent infringement trial victory against Box and Carahsoft Technology. OpenText is the largest independent software provider of Enterprise Information Management.

On February 13, 2015, a San Francisco federal court ruled that both Box and Carahsoft infringed, and induced others to infringe, claims on three OpenText patents. The jury found that Box Edit for Mac, Box Edit for Windows and the Box Android application all infringed. OpenText was awarded approximately $5 million in damages.

"This was an important win for OpenText and demonstrates our determination to protect our patents," said Gordon Davies, chief legal officer for OpenText. "The Cooley team fights to win. They are a key partner for us in this area, providing straight-up, creative and effective advice and advocacy."

Palo Alto, Calif. – Cooley advised the underwriters on FireEye's $303.5 million initial public offering. FireEye, a California-based technology company, invented a purpose-built, virtual machine-based security platform that provides real-time threat protection to enterprises and governments worldwide against the next generation of cyber attacks. FireEye now trades on the Nasdaq Global Market under the symbol "FEYE."

The underwriters include Morgan Stanley; Goldman Sachs; J.P. Morgan Securities; Barclays Capital; Merrill Lynch, Pierce, Fenner & Smith; UBS Securities; and Nomura Securities International.